Context Specificity of Gene Regulation
======================================

Transcription regulation is a complex system which includes enhancers and promoters, transcription factors and their binding sites, and regulatory RNAs such as long non-coding RNAs, that all act in highly cell type-specific manners to achieve appropriate levels of gene expression. To further our understanding of the non-coding genome, there is a range of different techniques needed to comprehensively investigate the regulatory elements, each with its own challenges and limitations (Box 1). Many large consortia, such as ENCODE ([@ddx254-B1]), Epigenome Roadmap ([@ddx254-B2]), Blueprint ([@ddx254-B3]) and FANTOM ([@ddx254-B4]), have used these techniques to systematically document the individual elements including enhancers and non-coding RNAs, in more than 100 different cell types and even under different conditions. These initiatives have moved the field of transcription regulation forward considerably, but have also clearly shown that especially enhancers and non-coding RNAs are extremely cell type- and condition-specific ([@ddx254-B2],[@ddx254-B5],[@ddx254-B6]) ([Fig. 1](#ddx254-F1){ref-type="fig"}). For example, *AP001057.1* is a long non-coding RNA (lncRNA) gene that is exclusively expressed in monocytes and upregulated upon induction with microbial agents. This lncRNA is located in a locus associated with coeliac disease and Crohn's disease ([@ddx254-B5]). Naturally, since the non-coding genome is cell type- and condition-specific manner, so too is the disruption of the non-coding genome by genetic variants associated with diseases.

![LncRNAs and enhancers are more cell-type-specific than protein-coding gene expression. Schematic representation of the correlation between the activities of protein-coding genes (purple), non-coding RNAs (blue) and enhancers (green).](ddx254f1){#ddx254-F1}

An important step in understanding the role of the non-coding genome in disease is to link disease-specific risk single nucleotide polymorphism (SNPs) to their target genes. This can be done in two ways: firstly, by identifying causal SNPs in non-coding regions and linking their function to causal genes, and secondly, by correlating gene expression with genotype. In many ways, the first approach is more informative, as the molecular mechanism for the causative effect on gene expression will be identified. However, identifying the true causal SNPs predisposing to disease is highly complicated because of the presence of linkage disequilibrium (LD) ([@ddx254-B7]), the phenomenon that multiple genetic variants close to each other are co-inherited together and therefore cannot be distinguished. But even within a long stretch of correlated SNPs, their evidence for being causal increases when they overlap enhancers ([@ddx254-B8]), when they disrupt predicted motifs including transcription factor binding sites ([@ddx254-B11]), and/or when they overlap evolutionary conserved regions ([@ddx254-B14]).

Alternatively, a powerful tool used in the second approach is *cis*-eQTL (expression quantitative trait loci) analysis, i.e. identifying genes whose level of expression is correlated with a close-by SNP. One example that shows the power of eQTL analysis is the obesity-associated SNP, rs1421085, that is located in one of the introns of the *FTO* gene. As there was no SNP that disrupted a protein-coding sequence, *FTO* was considered to be an excellent positional candidate gene. Many follow-up and functional studies have been conducted on *FTO* and led to more than 1,000 scientific articles, until Claussnitzer et al. discovered that rs1421085 affects the expression of *IRX3*, a transcription factor important for neuronal development, in brain tissue. Functional follow-up of *IRX3* offers convincing evidence for this gene playing a role in obesity ([@ddx254-B15]).

Examples of both approaches and the insights they have yielded on the role of genetics in autoimmune diseases are described later in this review.

Genetic Variants Associated with Autoimmune Disease Are Enriched in Regulatory Elements
=======================================================================================

Intersecting disease-associated SNPs with data on regulatory elements can be used to pinpoint causal variants among a set of SNPs in high LD. Autoimmune diseases have been prime examples for conducting such studies, as there are ample data on different immune cell types ([@ddx254-B1]). Performing such an analysis on SNPs associated with coeliac disease showed significant enrichment in B-cell-specific enhancers ([@ddx254-B16]). These results have not only helped to define potentially causal SNPs, but also imply an important role for B-cells in a disease that is traditionally regarded as a T-cell disorder. Trynka et al. ([@ddx254-B17]) showed that active non-coding regions in CD4+ regulatory T-cells overlapped with 31 SNPs associated with rheumatoid arthritis, implying a prominent role for these cells in its aetiology. The Epigenome Roadmap consortium, which has annotated regulatory elements based on epigenetic marks in 111 different primary tissues and cell types, both under resting and stimulated conditions, has allowed a systematic enrichment analysis to be performed ([@ddx254-B8]). Indeed, all autoimmune diseases display enrichment of SNPs in non-coding regions of different subsets of immune cells. Moreover, SNPs associated with type 1 diabetes overlap regulatory elements in pancreatic islets, while SNPs for Crohn's disease and ulcerative colitis are enriched in regulatory elements in the colonic mucosa ([@ddx254-B8]), indicating that cell types other than immune cells are also important in autoimmune diseases.

While enrichment analysis helps to prioritize potentially causal SNPs, it does not prove their causality. The most likely mechanism by which causal SNPs act is by disruption of transcription factor binding sites ([@ddx254-B11],[@ddx254-B13],[@ddx254-B15],[@ddx254-B18]). For example, SNPs associated with coeliac disease and rheumatoid arthritis disrupt binding sites of T-BET ([@ddx254-B19]), IRF1 ([@ddx254-B20]), AP-1 ([@ddx254-B8]) and of transcription factors that interact with IRF9 ([@ddx254-B11]). Surprisingly, only 1--20%, depending on the transcription factor, of the SNPs that disrupt a transcription factor binding site in a regulatory region also lead to changed activity of the regulatory element, either in a constitutive or cell-type-specific manner ([@ddx254-B15]); this is based on measuring allelic imbalance between the two different haplotypes ([Fig. 2](#ddx254-F2){ref-type="fig"}). Large-scale massive parallel reporter assays of eQTL-SNPs have identified SNPs that affect the activity of regulatory elements in lymphoblastoid cell lines ([@ddx254-B21]), including rs9283753, an SNP associated with ankylosing spondylitis that overlaps a distal enhancer of the prostaglandin E receptor 4 gene (*PTGER4*). Still, less than 3% of all the SNPs tested changed regulatory activity ([@ddx254-B21]). Overall, causal SNPs have not been identified for the vast majority of genetic loci associated with autoimmune diseases, which may be due to the fact that most epigenetic annotations are derived from cells under resting conditions whereas autoimmune disease SNPs that are prioritized to be causal seem to be enriched, mainly in stimulated cell types ([@ddx254-B8]).

![eQTLs can be cell-type-specific. Schematic representation of a genetic risk locus with variable effects on gene expression in *cis*, depending on cell type. From top to bottom: the cell type, the gene annotation track with SNPs (in red triangles), a cell-type-specific DHS-seq track displaying open chromatin regions (in black) and causal mutations and allele-specific open chromatin (in green and red); and the eQTL effects of causal mutations in each cell type. Left: gene X displays an eQTL effect in CD4^+^ T cells caused by a G-to-T mutation in an active enhancer. Right: in neutrophils, gene X is not differentially regulated by the G-to-T mutation, but gene Y is affected by an A-to-G mutation in the same locus.](ddx254f2){#ddx254-F2}

Finally, identification of causal SNPs is not enough to infer downstream effects of the SNPs active in disease. Therefore, causal SNPs and the non-coding regions they disrupt have to be linked to the affected genes. The most elegant way to do so is by mapping the looping interactions between non-coding regions and the genes they regulate by using chromatin capture techniques such as 4 C, promoter capture HiC and ChIA-PET (Box 1) ([@ddx254-B10],[@ddx254-B11],[@ddx254-B15],[@ddx254-B22],[@ddx254-B23]). This has prioritized multiple genes over long distances from the GWAS SNPs, including genes that are outside the typical *cis*-window of 500 kb-1 Mb (Megabase) used in *cis*-eQTL analysis. For example, *FOXO1* has an interaction with a non-coding region that overlaps a rheumatoid arthritis and juvenile idiopathic arthritis SNP over 1 Mb away ([@ddx254-B22]). However, 3D interaction data are not commonly generated, making it difficult to detect the loop between causal SNPs and genes. The Blueprint consortium ([@ddx254-B3]) has started to close this gap and analysed promoter capture HiC for 17 primary immune cell types ([@ddx254-B24]), thereby prioritizing 421 genes for autoimmune diseases based on GWAS summary statistics and 3D interaction data.

Thus, with increasing understanding of how the non-coding genome regulates gene expression in relevant cell types, it will be feasible to fine map and understand the mechanisms of causal SNPs in autoimmune disease.

SNPs Have Variable Effects Based on Cell Type and Context
=========================================================

Fine mapping and functionally linking causal SNPs to affected genes reveals a great deal about the molecular mechanisms by which SNPs affect autoimmune diseases, but does not allow for high-throughput detection of causal genes. So eQTL analysis is more commonly used as a direct way of detecting the effects of genetic variation on gene expression ([Fig. 2](#ddx254-F2){ref-type="fig"}).

Most large eQTL studies to date have used peripheral blood expression data ([@ddx254-B10],[@ddx254-B16],[@ddx254-B25]) and approximately 42% of SNPs associated with autoimmune diseases can be linked to a nearby gene by using gene expression data from peripheral blood ([@ddx254-B10]). These eQTL studies showed that disease SNPs can also affect the expression of long non-coding RNAs ([@ddx254-B10],[@ddx254-B31]), suggesting that risk SNPs may interfere with transcription regulation through regulatory RNAs. Although peripheral blood is likely to be appropriate for many of the SNPs associated with autoimmunity, risk SNPs for other diseases may fail to show an effect in blood and need to be investigated in other cell types. Moreover, how eQTL genes exert an effect in disease aetiology is difficult to interpret without knowing the cell type in which the gene is de-regulated due to genetic variants. Several strategies have been applied to circumvent these issues.

First, statistical methods can be applied to reassign eQTL signals to specific cell types or conditions in heterogeneous samples including peripheral blood ([@ddx254-B29],[@ddx254-B32],[@ddx254-B33]). The largest eQTL study to date classified 12% of over 23,000 eQTLs as cell-type-specific ([@ddx254-B29]). But a limitation is that these methods may not be able to capture a specific context including exposure to an antigen, or a rare cell type.

Alternatively, eQTL analysis can be performed in specific tissues, for example as done by the GTeX consortium and others ([@ddx254-B34]) or by sorting whole blood into its major cell types ([@ddx254-B12],[@ddx254-B18],[@ddx254-B20],[@ddx254-B37]). These approaches are much more expensive to perform and these eQTL studies are thus done on smaller cohorts and have reduced power. Nonetheless, many unique eQTLs have been identified by studies on specific cell types ([Figs 2 and 3](#ddx254-F2){ref-type="fig"}). For example, a neutrophil-specific change in the gene expression of protein-arginine deiminase type IV (*PADI-4*) due to the rheumatoid arthritis-associated SNP rs2240335 only overlaps with H3K27Ac marks in neutrophils, but not in monocytes and a further 450 out of 3281 neutrophil *cis*-eQTLs were not observed in non-neutrophil myeloid or lymphoid cell lineages ([@ddx254-B18]). Comparison of the highly related CD4^+^ and CD8^+^ T cells also identified interleukin 27 as a protective eQTL gene for type 1 diabetes exclusively in CD4^+^ T cells ([@ddx254-B40]).

![Cell-type- and context-specific eQTLs for coeliac disease. All lead SNPs from coeliac disease risk loci and proxy-SNPs in LD (*r*^2^\>0.8) were compared to peripheral blood eQTL studies and cell- and context-specific eQTL studies. eQTLs unique for these studies are shown along with the cell type and context in which they were identified.](ddx254f3){#ddx254-F3}

Not only the specific cell type may be important in identifying eQTLs, the context in which the cells operate is also relevant for autoimmune diseases, since these require interaction with auto-antigens for the disease to manifest ([Fig. 3](#ddx254-F3){ref-type="fig"}). Multiple studies have identified eQTLs that are not detected under resting conditions, but which appear strongly after stimulation ([@ddx254-B20],[@ddx254-B38],[@ddx254-B41],[@ddx254-B44]). This also depends on the stimulant and the time of stimulation, as Fairfax et al. have shown by stimulating monocytes with LPS for 2 hours and with LPS or interferon γ (IFNγ) for 24 hours ([@ddx254-B38]). Some genes even show opposing eQTL effects between stimulated and resting conditions (for example, *HIP1*, *STEAP4* and *CEACAM3*), or between different stimulants (*CEACAM3*), demonstrating how complex the contribution of SNPs to disease can be. So detecting cell-type- and condition-specific eQTLs increases detection of eQTLs in general and offers better interpretation of the role of the eQTL genes in disease aetiology.

Context-Specific Understanding of Autoimmune-Associated SNPs Important
======================================================================

To demonstrate how context- and cell-type-specific eQTL analysis can contribute to understanding autoimmune diseases, we have taken coeliac disease as an example. We extracted all the eQTL genes identified in a cell-type-specific context ([@ddx254-B12],[@ddx254-B18],[@ddx254-B20],[@ddx254-B35],[@ddx254-B40],[@ddx254-B42]), but not in peripheral blood ([@ddx254-B10],[@ddx254-B16],[@ddx254-B28],[@ddx254-B45]) ([Fig. 3](#ddx254-F3){ref-type="fig"}). Many of these genes have functions that are highly relevant for coeliac disease. For example, *REL*, encoding an Nuclear factor κB (NF-κB) subunit, is an eQTL in CD4^+^ T cells, the cell type that recognizes and responds to the gluten peptides that trigger coeliac disease and set in motion a chain of events leading to inflammation and an autoimmune response in the small intestines ([@ddx254-B9],[@ddx254-B48]). A major signalling pathway that regulates this response is NF-κB pathway ([@ddx254-B49]), so any changes in levels of NF-κB subunits in CD4^+^ T cells can have profound effects on the severity of the response to gluten peptides. Another example is protein tyrosine phosphatase non-receptor type 2 (*PTPN2*), which shows an eQTL effect in stimulated monocytes only ([Fig. 3](#ddx254-F3){ref-type="fig"}). *PTPN2* encodes a phosphatase involved in the monocyte response to IFNγ in inflammatory bowel disease (IBD) and rheumatoid arthritis ([@ddx254-B50]), thus a similar role in coeliac disease is possible since IFNγ is a major coeliac disease-associated cytokine ([@ddx254-B9],[@ddx254-B48],[@ddx254-B53]). To conclude, many genetic variants may have effects in a cell-type-specific manner, and detection of these effects can provide direct insights into disease mechanisms.

While these eQTLs have allowed us to prioritize the genes and pathways that are pivotal to disease aetiology, it is still unclear whether these genes are truly causal. Statistical tools that make use of the relationship between GWAS summary statistics and eQTL-SNP pairs to distinguish which eQTLs best explain the genetic effect on disease, have only been moderately successful ([@ddx254-B54]) and the lack of cell--type- and condition-specific eQTL data were given as one of the possible reasons for this ([@ddx254-B56]).

Therefore, it is critical to understand the conditions and circumstances in which autoimmune diseases occur. However, unlike coeliac disease, these circumstances are unknown for most autoimmune diseases and for coeliac disease many questions remain as well. Even though gluten peptides have been identified as the direct trigger of coeliac disease, the full context in which mucosal inflammation takes place is highly complex. Many cytokines including IFNγ, IL15 and IL21 play an important role ([@ddx254-B9],[@ddx254-B48],[@ddx254-B53]) and recently, Bouziat et al have shown that specific strains of Reovirus can invoke tolerance to gluten in mice, suggesting that virus infections can trigger coeliac disease ([@ddx254-B58]). Moreover, commensal gut microbes have also been implicated in coeliac disease ([@ddx254-B59]). Consequently, even for coeliac disease, it is nearly impossible to emulate the context in which genetic variants exert an effect on gene expression.

However, different stimuli have different effects on gene expression and the role of genetic variation might be specific to each separate stimulus. Comparative expression analysis of different pathogens has shown pathogen-specific gene expression changes in immune cells ([@ddx254-B20],[@ddx254-B60]) and production of variable levels of cytokines ([@ddx254-B61]). Moreover, cytokine production is influenced by genetic variants in a pathogen-specific manner ([@ddx254-B61], [@ddx254-B63]). So to truly capture the effects of genetic variation involved in autoimmune diseases, it may be necessary to analyse patient material as all the patient's conditions will be conducive to the pathology.

Concluding Remarks
==================

Since the association of genetic loci with autoimmune diseases, many eQTL and fine-mapping studies have been performed and made great strides in identifying putative causal genes and pathways affected by genetic variation associated with disease. However, the consequences of genetic variants may depend greatly on the cell type and conditions in which they are measured. As disease-specific cell types and conditions are often poorly defined in autoimmune disease, detection of eQTLs in patient-derived material may be the most straightforward way ([@ddx254-B35],[@ddx254-B36]). Unfortunately, the availability of material from sufficient numbers of patients and the amount of material itself are often limiting factors, making analysis of these samples difficult. However, sequencing techniques have improved over the years, making single-cell transcriptome and single-cell epigenome sequencing possible (Box 1). Moreover, statistical deconvolution of eQTL effects in solid tissues into single cell types is becoming increasingly sensitive ([@ddx254-B33],[@ddx254-B64]). Thus, with the use of statistical approaches and sophisticated techniques that require minimum amounts of input material, we can begin to discover the cell- and context-specific role of genetic variation in autoimmune disease.
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